Horizon Pharma plc to Present at the Cowen and Company 35th Annual Health Care Conference
(firmenpresse) - DUBLIN, IRELAND -- (Marketwired) -- 02/24/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients'' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present at the Cowen and Company 35th Annual Health Care Conference on Monday, March 2, 2015 at 2:10 p.m. Eastern Time in Boston, MA. Mr. Walbert will provide an overview of the Company and its corporate activities.
The presentation will be webcast live and may be accessed by visiting Horizon''s website at . A replay of the webcast will be available for 10 business days.
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients'' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon''s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon''s global headquarters are in Dublin, Ireland. For more information, please visit
Investors:
Robert F. Carey
Executive Vice President, Chief Business Officer
Media:
Geoff Curtis
DJE Science
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.02.2015 - 06:30 Uhr
Sprache: Deutsch
News-ID 1339342
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
DUBLIN, IRELAND
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Horizon Pharma plc to Present at the Cowen and Company 35th Annual Health Care Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Horizon Pharma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
